ArticleBMC infectious diseases2026
Generating hepatitis B and D monitoring indicators in Germany using claims data: number of persons tested, incident and prevalent infections, 2016-2021.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatitis B virus (HBV) infection remains one of the most common infectious diseases globally and can be exacerbated by coinfection with hepatitis D virus (HDV). In Germany, the incidence of hepatitis is reported annually through mandatory notification data. Nevertheless, these data lack information on hepatitis prevalence and testing coverage. We evaluated whether statutory health insurance claims data are suitable for continuous monitoring of key hepatitis indicators and whether they can complement existing HBV and HDV surveillance with reliable, population-based estimates.
methodsWe conducted a population-based cohort study using anonymised claims data from an age- and gender-representative sample from the InGef (Institute for Applied Health research) database between 2016 and 2021. We retrospectively analysed monitoring indicators for HBV and HDV -including annual prevalent infections within the respective analysis year, incidence of newly detected HBV infections (defined using a 3-year diagnosis-free interval) and the number of persons tested- based on coded diagnoses among individuals with access to healthcare services. Results were extrapolated to the German total population.
resultsBetween 1,996 and 2,066 persons per 100,000 population were tested annually for at least one HBV marker (HBsAg or Anti-HBc), with 97% undergoing HBsAg testing only. The proportion of annual prevalent HBV infections ranged from 0.14% to 0.15% between 2016 and 2020. Incidence of newly detected HBV infections (3-year diagnosis-free interval) declined from 13.5 per 100,000 in 2019 to 8.9 per 100,000 in 2020. The proportion of prevalent HDV infections among HBV-positive persons varied from 4.5 to 6.4%.
conclusionsClaims data provide a viable basis for continuous monitoring of selected hepatitis indicators in Germany. The number of prevalent and incident infections is consistent with other data sources and we were able to estimate the number of persons tested for hepatitis, addressing an important data gap. Claims data complement current surveillance systems and provide information for targeted public health action. The established approach should be applied to generate further hepatitis monitoring indicators.
trial registrationClinical trial number: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.